as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹31.51
Change
+2.86 (9.98%)
Open
₹28.78
Prev. Close
₹28.65
Day High
₹31.51
Day Low
₹27.71
Volume Analysis
Traded
80,210,539
Delivered
12,778,150
Delivery %
15.93%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Trading within 3% of its 52-week high (₹31.3)
- •Strong operating margin (28.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹36.57 | ₹34.04 | ₹32.77 | ₹30.24 | ₹28.97 | ₹26.44 | ₹25.17 |
| Fibonacci | ₹34.04 | ₹32.59 | ₹31.69 | ₹30.24 | ₹28.79 | ₹27.89 | ₹26.44 |
| Camarilla | ₹32.56 | ₹32.21 | ₹31.86 | ₹30.24 | ₹31.16 | ₹30.81 | ₹30.47 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-78.76%
1 Week
+20.08%
1 Month
+98.05%
3 Months
+97.06%
6 Months
-72.13%
1 Year
-75.51%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹7.25
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
12.64%
Net margin 16.86% × asset turnover 0.46x × equity multiplier 1.63x
Company Overview
Sector
Healthcare
Market Cap
₹1,655 Cr
P/E (TTM)
52.3
ROE
18.4%
Book Value
₹4.33
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Anlon Healthcare Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 56/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹31.3); strong operating margin (28.0%). FII holding has been rising.
TopFund Score — Fundamentals Quality
56/100 — AverageData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- −Stock is trading at 7.20 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has high debtors of 220 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Management will participate in Arihant Capital’s Bharat Connect Conference Rising Stars 2026 on 29 September 2026.
Anlon Healthcare incorporated 90%-owned Nigeria subsidiary on September 20, 2026 to expand West African operations.
Shareholders approved share swap to acquire 44.94% Apiqo Organics and 47.41% Bizotic Lifescience; issue price ₹17.85.
Company says no undisclosed event; price movement appears market-driven.
Exchange has sought clarification from Anlon Healthcare Ltd on September 16, 2026 with reference to significant movement in price, in order to ensure that investors …
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales + | 49 | 33 | 36 | 51 | 88 |
| Expenses + | 32 | 27 | 23 | 36 | 72 |
| Operating Profit | 17 | 6 | 12 | 15 | 16 |
| OPM % | 35.13% | 18.74% | 34.51% | 30.05% | 17.8% |
| Other Income + | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 2 | 1 | 1 |
| Depreciation | 1 | 0 | 0 | 0 | 1 |
| Profit before tax | 15 | 5 | 11 | 14 | 14 |
| Tax % | -7.49% | 29.2% | 51.41% | 23.34% | 39.39% |
| Net Profit + | 17 | 4 | 5 | 11 | 8 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales + | 120 | 172 |
| Expenses + | 88 | 124 |
| Operating Profit | 32 | 48 |
| OPM % | 27.0% | 28.0% |
| Other Income + | 0 | 0 |
| Interest | 4 | 4 |
| Depreciation | 2 | 2 |
| Profit before tax | 27 | 43 |
| Tax % | 24.0% | 32.0% |
| Net Profit + | 21 | 29 |
| EPS in Rs | 1 | 1 |
| Dividend Payout % | 0.0% | 0.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Reserves | 41 | 177 |
| Borrowings + | 67 | 44 |
| Other Liabilities + | 34 | 100 |
| Total Liabilities | 181 | 374 |
| Fixed Assets + | 23 | 58 |
| CWIP | 0 | 0 |
| Investments | 1 | 1 |
| Other Assets + | 158 | 315 |
| Total Assets | 181 | 374 |
| Equity Capital | 40 | 53 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity + | -22 | -59 |
| Cash from Investing Activity + | 2 | -36 |
| Cash from Financing Activity + | 19 | 118 |
| Net Cash Flow | -1 | 23 |
| CFO/OP | -85 | -114 |
| Free Cash Flow | -19 | -95 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Public | 44.49% | 42.6% | 42.4% | 44.43% |
| Promoters | 52.68% | 52.68% | 52.68% | 52.68% |
| FII | 0.0% | 0.23% | 0.32% | 1.67% |
| DII | 2.83% | 4.49% | 4.6% | 1.23% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Anlon Healthcare Limited (this stock) | 1,655 | 52.3 | 7.18 | 18.4% |
| Shalby Limited | 1,589 | 40.4 | 1.58 | 2.45% |
| Tarsons Products Limited | 1,770 | 150.0 | 2.8 | 2.44% |
| Krsnaa Diagnostics Ltd | 1,785 | 18.3 | 1.81 | 10.9% |
| Suraksha Diagnostic Ltd | 1,788 | 49.9 | 7.3 | 14.2% |
| Ngl Fine Chem Limited | 1,796 | 31.4 | 5.45 | 17.4% |
| Amrutajan Health Ltd | 1,480 | 72.6 | 13.76 | 20.0% |
Which Mutual Funds Hold Anlon Healthcare Limited?
Frequently Asked Questions about Anlon Healthcare Limited
Anlon Healthcare Limited (AHCL) closed at ₹31.51 on NSE on 25 September 2026, up 2.86 (9.98%) from the previous close.
Anlon Healthcare Limited trades on the NSE (National Stock Exchange of India) under the symbol AHCL.
Anlon Healthcare Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 52.3.
Anlon Healthcare Limited has a dividend yield of 0.0%.
Anlon Healthcare Limited's 52-week high is ₹31.3 and its 52-week low is ₹10.3.
Anlon Healthcare Limited has a market capitalisation of ₹1,655 crore.
Anlon Healthcare Limited has a TopFund Quality Score of 56/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Anlon Healthcare Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.